Stock Market Reviews

LNTH (Lantheus Holdings, Inc.) News

Get the latest news, insights, and market updates on LNTH (Lantheus Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Lantheus closes SPECT business sale to SHINE Technologies
  Lantheus (LNTH) Holdings completed the previously announced sale of its single photon emission computed tomography business to SHINE Technologies. Under the terms of the agreement, SHINE has acquired Lantheus’ SPECT business, including its diagnostic agents, the portion of the North Billerica, Massachusetts campus that manufactures Lantheus’ SPECT products, and the SPECT-related Canadian operations. With the SPECT divestiture finalized, Lantheus will focus on its growing commercial portfolio of
  Jan 3, 2026 - $LNTH
• Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
  BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under
  Jan 2, 2026 - $LNTH
• 2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 11.5%, nearly mirrorring the S&P 500.
  Jan 1, 2026 - $LNTH
• Lantheus Exit: $28 Million Sale Comes as Earnings Fall 77% Year Over Year
  The move suggests that shrinking margins, leadership turnover, and a shifting product mix are quietly reshaping the Lantheus investment case.
  Dec 23, 2025 - $LNTH
• This Healthcare Stock Still Commands a Top 3 Portfolio Slot Despite a Steep Slide This Past Year
  After a bruising year for the stock, one fund leaned further into a business throwing off real cash and quietly reshaping its growth engine.
  Dec 23, 2025 - $LNTH
• Spotting Winners: Lantheus (NASDAQ:LNTH) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q3
  As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
  Dec 22, 2025 - $LNTH
• Truist Sees Upside in Lantheus Holdings, Inc. (LNTH) Despite PYLARIFY Pressure
  We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. LNTH is one of them. On December 11, TheFly reported that Truist Securities upgraded LNTH from Hold to Buy and raised its price target to $80, reflecting a more optimistic view of the company’s growth prospects and belief that the […]
  Dec 17, 2025 - $LNTH
• 2 Russell 2000 Stocks with Exciting Potential and 1 We Brush Off
  The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
  Dec 16, 2025 - $LNTH
• Lantheus Holdings (LNTH) Is Up 5.2% After Truist Upgrade Highlighting Underappreciated Profit Potential – Has The Bull Case Changed?
  Earlier this month, radiopharmaceutical company Lantheus Holdings received an upgrade from Truist Securities to “Buy,” with the firm highlighting stronger growth and profitability potential from late 2026 onward. This upgrade adds to a generally positive analyst backdrop for Lantheus, with many firms citing the company’s solid financial profile and competitive operating margins as underappreciated strengths. We’ll now explore how Truist’s more optimistic view of Lantheus’s long-term growth...
  Dec 14, 2025 - $LNTH
• Reassessing Lantheus Holdings After Recent Share Price Volatility and Cash Flow Outlook
  If you are wondering whether Lantheus Holdings is a bargain after its rollercoaster ride over the last few years, you are not alone. That is exactly what this breakdown is here to tackle. Despite being down 25.0% year to date and 28.4% over the last year, the stock has bounced 5.2% in the past week and 25.7% over the last month, hinting that sentiment around its long term story might be turning. Recently, investors have focused on Lantheus role in diagnostic imaging and radiopharmaceuticals...
  Dec 14, 2025 - $LNTH